CL2013001403A1 - Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso. - Google Patents

Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.

Info

Publication number: CL2013001403A1
Authority: CL; Chile
Prior art keywords: encodes; vector; nucleic acid; composition; production
Prior art date: 2010-11-19

Application number

CL2013001403A

Other languages

English (en)

Inventor

Toshio Imai

Luigi Grasso

James Bradford Kline

Tetsu Kawano

Yoshimasa Sakamoto

Jared Spidel

Miyuki Nishimura

Kenzo Muramoto

Tatsuo Horizoe

Original Assignee

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-19

Filing date

2013-05-17

Publication date

2014-08-08

2013-05-17 Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd

2014-08-08 Publication of CL2013001403A1 publication Critical patent/CL2013001403A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biophysics (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Virology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)

CL2013001403A 2010-11-19 2013-05-17 Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso. CL2013001403A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41561410P	2010-11-19	2010-11-19

Publications (1)

Publication Number	Publication Date
CL2013001403A1 true CL2013001403A1 (es)	2014-08-08

Family

ID=46084688

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001403A CL2013001403A1 (es)	2010-11-19	2013-05-17	Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.

Country Status (25)

Country	Link
US (3)	US8491901B2 (es)
EP (1)	EP2640744A4 (es)
JP (3)	JP5996549B2 (es)
KR (1)	KR101919170B1 (es)
CN (1)	CN103874707B (es)
AR (1)	AR084141A1 (es)
AU (2)	AU2011329647B2 (es)
BR (1)	BR112013012396A2 (es)
CA (1)	CA2818548A1 (es)
CL (1)	CL2013001403A1 (es)
CO (1)	CO6761352A2 (es)
CR (1)	CR20130228A (es)
DO (1)	DOP2013000111A (es)
EA (1)	EA029419B1 (es)
IL (1)	IL226383B (es)
MA (1)	MA34738B1 (es)
MX (1)	MX361929B (es)
NZ (1)	NZ611269A (es)
PE (2)	PE20180249A1 (es)
PH (1)	PH12013500990A1 (es)
SG (2)	SG10201509499RA (es)
TW (1)	TWI589587B (es)
UA (1)	UA114077C2 (es)
WO (1)	WO2012068540A2 (es)
ZA (3)	ZA201303571B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20180249A1 (es) *	2010-11-19	2018-02-02	Eisai Randd Man Co Ltd	Anticuerpos neutralizadores anti-ccl20
AU2013221585B2 (en)	2012-02-17	2017-03-30	Seagen Inc.	Antibodies to integrin alphavbeta6 and use of same to treat cancer
WO2014062659A2 (en) *	2012-10-15	2014-04-24	Oncomed Pharmaceuticals, Inc.	Methods of treating ocular diseases
EP3689325A1 (en)	2014-04-08	2020-08-05	Boston Pharmaceuticals Inc.	Binding molecules specific for il-21 and uses thereof
MX2016015181A (es)	2014-05-21	2017-05-25	Pfizer	Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MA41480A (fr) *	2014-10-17	2017-12-19	Glenmark Pharmaceuticals Sa	Anticorps qui se lient au ccr6 et leurs utilisations
US10647766B2 (en) *	2014-12-17	2020-05-12	Cancer Research Technology Limited	Anti-CXCL12 antibody molecules and their uses
US11571462B2 (en)	2015-06-03	2023-02-07	The Medical College Of Wisconsin, Inc.	Engineered CCL20 locked dimer polypeptide
EP3666282A1 (en)	2015-06-03	2020-06-17	The Medical College of Wisconsin, Inc.	An engineered ccl20 locked dimer polypeptide
KR20180027568A (ko) *	2015-07-14	2018-03-14	메디뮨 엘엘씨	암을 치료하기 위한 조성물 및 방법
WO2017064564A2 (en) *	2015-10-16	2017-04-20	Glaxosmithkline Intellectual Property Limited	Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody
BR112018014908A2 (pt) *	2016-01-21	2018-12-18	The Scripps Research Institute	vacina de opioide sintético
CA3010224A1 (en)	2016-01-22	2017-07-27	Merck Sharp & Dohme Corp.	Anti-coagulation factor xi antibodies
AU2017286432B2 (en)	2016-06-14	2020-09-24	Adimab, Llc	Anti-coagulation factor XI antibodies
WO2018088877A2 (ko) *	2016-11-14	2018-05-17	다이노나(주)	CD66c에 특이적으로 결합하는 항체 및 그의 용도
FR3072779A1 (fr) *	2017-10-19	2019-04-26	Sinnovial	Procede d'estimation de l'efficacite d'un modulateur de la costimulation des lymphocytes t contre la polyarthrite rhumatoide apres reponse inadequate a une biotherapie
WO2019094608A1 (en)	2017-11-08	2019-05-16	Denali Therapeutics Inc.	Anti-bace1 antibodies and methods of use thereof
CA3082365A1 (en)	2017-11-09	2019-05-16	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2020185952A1 (en) *	2019-03-11	2020-09-17	xCella Biosciences, Inc.	Cd27-binding antibodies and uses thereof
US11827709B2 (en) *	2019-12-05	2023-11-28	Seagen Inc.	Anti-AVB6 antibodies and antibody-drug conjugates
CN113087795B (zh) *	2019-12-23	2025-06-10	上海普铭生物科技有限公司	针对趋化因子cx3cl1的抗体及其应用
US12129302B2 (en)	2021-08-25	2024-10-29	Ibio, Inc.	Anti-CD-25 antibody
CN117209603B (zh) *	2021-12-02	2024-02-27	北京东方百泰生物科技股份有限公司	一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN120518761B (zh) *	2023-06-05	2025-12-26	北京东方百泰生物科技股份有限公司	一种结合il-11的抗体、其抗原结合片段及应用
CN119139478A (zh) *	2024-10-11	2024-12-17	首都医科大学附属北京胸科医院	一种治疗anxa6+egfr突变的肺腺癌的组合物

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4897348A (en)	1983-08-25	1990-01-30	Sri International	Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
JPH02500329A (ja)	1987-05-21	1990-02-08	クリエイテイブ・バイオマリキユールズ・インコーポレーテツド	ターゲット化多機能蛋白質
US5750172A (en)	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
WO1989007142A1 (en)	1988-02-05	1989-08-10	Morrison Sherie L	Domain-modified constant region antibodies
WO1990006321A1 (en)	1988-12-08	1990-06-14	Sandoz Ag	Neutrophil-activating peptide-2
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5212073A (en)	1989-05-12	1993-05-18	Genetics Institute, Inc.	Process for producing human JE cytokine
US5179078A (en)	1989-05-12	1993-01-12	Dana Farber Cancer Institute	Method of suppressing tumor formation in vivo
DE69020573T3 (de)	1989-09-25	1999-12-16	Crc Technology Ltd., London	Verfahren zur wachstumshemmung von stammzellen.
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6750325B1 (en)	1989-12-21	2004-06-15	Celltech R&D Limited	CD3 specific recombinant antibody
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
NZ237202A (en)	1990-02-23	1994-01-26	Bristol Myers Squibb Co	Composition containing beta-lactam antibiotic and cationic oligopeptide
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
ATE177472T1 (de)	1990-09-14	1999-03-15	Chiron Corp	Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen
US6001649A (en)	1990-11-29	1999-12-14	Societe Anonyme: Elf Sanofi	Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
US5401651A (en)	1991-10-16	1995-03-28	Walz; Alfred	DNA encoding ENA-78, a neutrophil activating factor
US5306709A (en)	1991-11-15	1994-04-26	The University Of Pennsylvania	Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5413778A (en)	1992-10-05	1995-05-09	The Regents Of The University Of Michigan	Labelled monocyte chemoattractant protein material and medical uses thereof
US5346686A (en)	1992-10-05	1994-09-13	Mallinckrodt Medical, Inc.	Labelled interleukin-8 and medical uses thereof
WO1994019935A1 (en)	1993-03-09	1994-09-15	Genzyme Corporation	Isolation of components of interest from milk
US5474983A (en)	1993-03-15	1995-12-12	The Research Foundation Of State University Of New York	Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
WO1994026087A2 (en)	1993-05-14	1994-11-24	Connor Kim C O	Recombinant protein production and insect cell culture and process
JPH08511420A (ja)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	抗体
JPH0789866A (ja)	1993-09-21	1995-04-04	Nippon Kayaku Co Ltd	感染防御剤
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
KR970700438A (ko)	1993-12-22	1997-02-12	로버트 에이치. 벤슨	마크로파지 염증성 단백질-3,-4 및 -1감마(MACROPHAGE INFLAMMATORY PROTEINS -3,-4 AND -1sg(g))
AU7394294A (en)	1994-05-16	1995-12-05	Human Genome Sciences, Inc.	Macrophage migration inhibitory factor-3
ATE206162T1 (de)	1994-05-16	2001-10-15	Human Genome Sciences Inc	Chemotaktisches protein
US6518046B1 (en)	1994-08-23	2003-02-11	Human Genome Sciences, Inc.	Human chemokine β-9
US6458349B1 (en)	1995-06-02	2002-10-01	Human Genome Sciences, Inc.	Chemokine β-4 polypeptides
US6174995B1 (en)	1994-08-23	2001-01-16	Haodong Li	Human chemokines, CKβ4 and CKβ10/MCP-4
US5981230A (en)	1994-08-23	1999-11-09	Human Genome Sciences, Inc.	Polynucleotide encoding chemokine β-4
DK0777494T3 (da)	1994-08-23	2004-07-26	Human Genome Sciences Inc	Humane kemokin-polypeptider
EP0777494B1 (en)	1994-08-23	2004-03-24	Human Genome Sciences, Inc.	Human chemokine polypeptides
WO1996005856A1 (en)	1994-08-23	1996-02-29	Human Genome Sciences, Inc.	Human chemokine polypeptides
WO1996009062A1 (en)	1994-09-23	1996-03-28	University Of Nebraska Board Of Regents	Polypeptide agonists and antagonists of human interleukin-8
CA2203655C (en)	1994-11-07	2010-03-23	Guo-Liang Yu	Tumor necrosis factor-gamma
US5602008A (en)	1994-11-29	1997-02-11	Incyte Pharmaceuticals, Inc.	DNA encoding a liver expressed chemokine
US6046037A (en)	1994-12-30	2000-04-04	Hiatt; Andrew C.	Method for producing immunoglobulins containing protection proteins in plants and their use
EP0822984A4 (en)	1995-04-27	2000-05-03	Human Genome Sciences Inc	TUMOR NECROSIS FACTOR RECEPTORS IN MEN
JPH11507224A (ja)	1995-06-05	1999-06-29	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	ヒトケモカインβ−１１およびヒトケモカインα−１
ATE278780T1 (de)	1995-06-06	2004-10-15	Human Genome Sciences Inc	Humanes chemokin beta-13
AU2698795A (en)	1995-06-06	1996-12-24	Human Genome Sciences, Inc.	Human chemokine beta-12
ZA968897B (en)	1995-10-24	1998-07-14	Smithkline Beecham Corp	Novel chemokine for mobilizing stem cells
ZA968896B (en)	1995-10-24	1997-04-24	Smithkline Beecham Corp	Method of mobilizing hematopoietic stem cells
WO1997031098A1 (en)	1996-02-23	1997-08-28	Human Genome Sciences, Inc.	Human chemokine polypeptides
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
WO1997035982A2 (en)	1996-03-27	1997-10-02	Icos Corporation	Monocyte chemotactic protein-5 materials and methods
US6290948B1 (en)	1996-05-14	2001-09-18	Smithkline Beecham Corporation	Method of treating sepsis and ARDS using chamohine beta-10
AU3574997A (en)	1996-07-05	1998-02-02	Schering Corporation	Mammalian chemokine reagents
AU4055697A (en)	1996-08-16	1998-03-06	Schering Corporation	Mammalian cell surface antigens; related reagents
EP2025682A3 (en)	1996-08-16	2009-06-17	Human Genome Sciences, Inc.	Human endokine alpha
GB9617923D0 (en)	1996-08-28	1996-10-09	Smithkline Beecham Plc	Novel receptor
WO1998011226A2 (en)	1996-09-10	1998-03-19	Schering Corporation	Mammalian chemokines, related reagents
WO1998014573A1 (en)	1996-09-30	1998-04-09	The General Hospital Corporation	Mcp-4 and mcp-5: novel chemokines
WO1998017800A1 (fr)	1996-10-17	1998-04-30	Shionogi & Co., Ltd.	Larc, nouvelle chimiokine cc humaine
CA2266439C (en)	1996-10-25	2009-06-16	Human Genome Sciences, Inc.	Neutrokine .alpha.
JP2001516203A (ja)	1996-11-15	2001-09-25	アドバンストリサーチアンドテクノロジーインスティチュート	エクソダスケモカイン物質及び方法
US7101987B2 (en) *	1996-11-27	2006-09-05	Schering Corporation	CCL27 polypeptides
JP2001507937A (ja)	1997-01-14	2001-06-19	ヒューマンジノームサイエンシーズ，インコーポレイテッド	腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β
ATE321855T1 (de)	1997-01-14	2006-04-15	Human Genome Sciences Inc	Tumor-nekrose-faktor rezeptor 5
EP1862548A1 (en)	1997-01-28	2007-12-05	Human Genome Sciences, Inc.	Death domain containing receptor 4 (DR4 : death receptor 4), member of the TNF-receptor superfamily and binding to trail (APO2-L)
CA2285040C (en)	1997-03-17	2009-01-27	Human Genome Sciences, Inc.	Death domain containing receptor 5
US6972323B1 (en)	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
WO1998049309A1 (en)	1997-04-30	1998-11-05	F. Hoffmann-La Roche Ag	Rat st38.2 chemokine
DE69833755T2 (de)	1997-05-21	2006-12-28	Biovation Ltd.	Verfahren zur herstellung von nicht-immunogenen proteinen
US6214580B1 (en)	1997-05-30	2001-04-10	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr10
EP0988371A4 (en)	1997-06-11	2002-11-04	Human Genome Sciences Inc	TR9 HUMAN RECEPTOR OF TUMOR NECROSIS FACTOR
CA2323093A1 (en)	1998-03-18	1999-09-23	Corixa Corporation	Compounds and methods for therapy and diagnosis of lung cancer
WO2000009560A2 (en)	1998-08-17	2000-02-24	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
EP1051432B1 (en)	1998-12-08	2007-01-24	Biovation Limited	Method for reducing immunogenicity of proteins
JP2002540068A (ja) *	1999-02-03	2002-11-26	シェーリングコーポレイション	治療におけるｍｉｐ−３ａのアゴニストまたはアンタゴニストの使用
US6645491B1 (en)	1999-02-03	2003-11-11	Schering Corporation	Method for treating inflammatory conditions using an antibody to MIP-3α
WO2001066754A1 (en)	2000-03-03	2001-09-13	Cambridge Antibody Technology Limited	Human antibodies against eotaxin and their use
WO2002032456A1 (en)	2000-10-13	2002-04-25	Teijin Limited	Remedies or preventives for rheumatoid arthritis
ATE414720T1 (de) *	2000-12-05	2008-12-15	Alexion Pharma Inc	Rationell entworfene antikörper
US7468253B2 (en)	2001-06-07	2008-12-23	Chemocentryx, Inc.	Method for multiple chemokine receptor screening for antagonists using RAM assay
EP1717583A3 (en)	2001-06-07	2007-10-10	ChemoCentryx Inc	Cell migration assay
US7442512B2 (en)	2001-11-30	2008-10-28	Chemocentryx, Inc.	Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DE60226641D1 (de)	2001-12-03	2008-06-26	Amgen Fremont Inc	Antikörperkategorisierung auf der grundlage von bindungseigenschaften
CA2484121A1 (en)	2002-05-01	2003-11-13	Human Genome Sciences, Inc.	Antibodies that specifically bind to chemokine beta-4
EP1592387A4 (en)	2003-01-24	2009-05-06	Elan Pharm Inc	COMPOSITION AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
JP4644663B2 (ja)	2003-06-03	2011-03-02	セルジェネシスインコーポレイテッド	ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
WO2005042581A2 (en)	2003-11-01	2005-05-12	Biovation Ltd.	Modified anti-cd52 antibody
EP1812062B1 (en) *	2004-10-25	2022-03-09	Merck Sharp & Dohme Corp.	Anti-addl antibodies and uses thereof
ES2905923T3 (es)	2005-02-08	2022-04-12	Genzyme Corp	Anticuerpos de TGFbeta
JP2009096716A (ja) *	2006-01-19	2009-05-07	Eisai R & D Management Co Ltd	抗ｃｃｌ２０抗体による自己免疫疾患の治療
WO2009062050A2 (en) *	2007-11-08	2009-05-14	Neogenix Oncology, Inc.	Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CA2708854C (en) *	2007-12-14	2017-11-28	Novo Nordisk A/S	Antibodies against human nkg2d and uses thereof
WO2009156994A1 (en) *	2008-06-24	2009-12-30	Hadasit Medical Research Services And Development Ltd.	Ccl20-specific antibodies for cancer therapy
AU2009299793B2 (en) *	2008-10-01	2016-03-10	Amgen Research (Munich) Gmbh	Bispecific single chain antibodies with specificity for high molecular weight target antigens
PE20180249A1 (es) *	2010-11-19	2018-02-02	Eisai Randd Man Co Ltd	Anticuerpos neutralizadores anti-ccl20
WO2013005649A1 (ja) *	2011-07-01	2013-01-10	協和発酵キリン株式会社	抗ヒトｃｃｒ６抗体
JP7089866B2 (ja)	2017-12-22	2022-06-23	セーレン株式会社	開口部を有するシート状物およびその製造方法

2011
- 2011-11-18 PE PE2017002493A patent/PE20180249A1/es unknown
- 2011-11-18 MX MX2013005532A patent/MX361929B/es active IP Right Grant
- 2011-11-18 PH PH1/2013/500990A patent/PH12013500990A1/en unknown
- 2011-11-18 EP EP11841462.2A patent/EP2640744A4/en not_active Withdrawn
- 2011-11-18 KR KR1020137015726A patent/KR101919170B1/ko not_active Expired - Fee Related
- 2011-11-18 EA EA201390738A patent/EA029419B1/ru not_active IP Right Cessation
- 2011-11-18 JP JP2013540086A patent/JP5996549B2/ja active Active
- 2011-11-18 WO PCT/US2011/061525 patent/WO2012068540A2/en not_active Ceased
- 2011-11-18 UA UAA201307767A patent/UA114077C2/uk unknown
- 2011-11-18 PE PE2013001216A patent/PE20140633A1/es active IP Right Grant
- 2011-11-18 AR ARP110104320 patent/AR084141A1/es not_active Application Discontinuation
- 2011-11-18 BR BR112013012396-6A patent/BR112013012396A2/pt not_active Application Discontinuation
- 2011-11-18 CN CN201180063873.1A patent/CN103874707B/zh not_active Expired - Fee Related
- 2011-11-18 CA CA 2818548 patent/CA2818548A1/en not_active Abandoned
- 2011-11-18 AU AU2011329647A patent/AU2011329647B2/en not_active Ceased
- 2011-11-18 US US13/300,352 patent/US8491901B2/en active Active
- 2011-11-18 SG SG10201509499RA patent/SG10201509499RA/en unknown
- 2011-11-18 SG SG2013038245A patent/SG191716A1/en unknown
- 2011-11-18 NZ NZ61126911A patent/NZ611269A/en not_active IP Right Cessation
- 2011-11-18 TW TW100142487A patent/TWI589587B/zh not_active IP Right Cessation
2013
- 2013-05-16 ZA ZA2013/03571A patent/ZA201303571B/en unknown
- 2013-05-16 IL IL226383A patent/IL226383B/en active IP Right Grant
- 2013-05-17 DO DO2013000111A patent/DOP2013000111A/es unknown
- 2013-05-17 CR CR20130228A patent/CR20130228A/es unknown
- 2013-05-17 CL CL2013001403A patent/CL2013001403A1/es unknown
- 2013-06-14 MA MA36013A patent/MA34738B1/fr unknown
- 2013-06-19 CO CO13145744A patent/CO6761352A2/es unknown
- 2013-06-21 US US13/924,433 patent/US9133273B2/en active Active
2014
- 2014-08-15 ZA ZA2014/06017A patent/ZA201406017B/en unknown
2015
- 2015-08-03 US US14/816,989 patent/US9809647B2/en active Active
2016
- 2016-01-21 AU AU2016200359A patent/AU2016200359B2/en not_active Ceased
- 2016-02-10 JP JP2016023617A patent/JP6289520B2/ja active Active
2017
- 2017-02-10 ZA ZA2017/01051A patent/ZA201701051B/en unknown
- 2017-12-26 JP JP2017249641A patent/JP2018042578A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP5996549B2 (ja)	2016-09-21
CA2818548A1 (en)	2012-05-24
WO2012068540A3 (en)	2012-09-27
CN103874707A (zh)	2014-06-18
CN103874707B (zh)	2017-04-19
AU2016200359B2 (en)	2018-05-24
KR20130135872A (ko)	2013-12-11
SG10201509499RA (en)	2015-12-30
US20160046707A1 (en)	2016-02-18
TW201305204A (zh)	2013-02-01
AU2011329647B2 (en)	2015-10-22
WO2012068540A2 (en)	2012-05-24
ZA201701051B (en)	2018-05-30
JP6289520B2 (ja)	2018-03-07
EP2640744A2 (en)	2013-09-25
CO6761352A2 (es)	2013-09-30
IL226383B (en)	2018-07-31
EP2640744A4 (en)	2014-05-28
PE20180249A1 (es)	2018-02-02
BR112013012396A2 (pt)	2020-11-10
AU2016200359A1 (en)	2016-02-11
EA201390738A1 (ru)	2013-12-30
NZ611269A (en)	2015-03-27
US20140045215A1 (en)	2014-02-13
IL226383A0 (en)	2013-07-31
DOP2013000111A (es)	2014-06-15
US8491901B2 (en)	2013-07-23
JP2016093195A (ja)	2016-05-26
UA114077C2 (xx)	2017-04-25
ZA201303571B (en)	2014-12-23
US9809647B2 (en)	2017-11-07
AU2011329647A1 (en)	2013-05-02
MA34738B1 (fr)	2013-12-03
EA029419B1 (ru)	2018-03-30
PE20140633A1 (es)	2014-05-30
CR20130228A (es)	2013-09-18
AR084141A1 (es)	2013-04-24
SG191716A1 (en)	2013-08-30
US20120148592A1 (en)	2012-06-14
MX361929B (es)	2018-12-19
PH12013500990A1 (en)	2022-11-23
TWI589587B (zh)	2017-07-01
JP2014502154A (ja)	2014-01-30
ZA201406017B (en)	2017-06-28
JP2018042578A (ja)	2018-03-22
KR101919170B1 (ko)	2018-11-15
US9133273B2 (en)	2015-09-15
MX2013005532A (es)	2013-09-26

Publication	Publication Date	Title
CL2013001403A1 (es)	2014-08-08	Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2011002304A1 (es)	2012-04-09	Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer.
CL2013001279A1 (es)	2014-03-07	Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
CL2013000566A1 (es)	2014-01-24	Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2009000459A1 (es)	2010-12-10	Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2011000084A1 (es)	2011-07-01	Anticuerpo monoclonal o fragmento enlazante a antigeno del mismo que se une al citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; y composicion que lo comprende.
CY1122978T1 (el)	2021-10-29	Αντισωματα εναντι-vla-4
CL2014000631A1 (es)	2014-09-26	Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2013000074A1 (es)	2013-12-06	Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
BR112014004168A2 (pt)	2017-12-12	anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
CL2011002611A1 (es)	2012-07-20	Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17.
CL2013000369A1 (es)	2014-08-08	Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2008002444A1 (es)	2009-09-04	Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
CL2014000699A1 (es)	2014-09-12	Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
CL2013001625A1 (es)	2014-02-21	Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa.
CL2013002039A1 (es)	2014-03-07	Anticuerpo aislado o fragmento del mismo que se une especificamente a il-13; molecula de acido nucleico que lo codifica; vector; celula; composicion farmaceutica que lo comprende; y su uso (div.sol.n°3037-08).
CL2015001709A1 (es)	2015-08-28	Etiqueta de péptido que se une a hialuronano; ácido nucleico que la codifica; vector; célula hospedera; molécula etiquetada con dicho péptido; composición que la comprende; y método de producción de etiqueta de péptido.
MX372950B (es)	2020-04-03	Anticuerpos.
EA201492101A1 (ru)	2015-04-30	Антитела против fcrn
CL2013001776A1 (es)	2014-03-07	Anticuerpo aislado que se une a mesotelina; acido nucleico que la codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que lo comprende; su uso para tratar cancer; y metodo de deteccion de mesotelina humana.
CL2011002360A1 (es)	2012-07-20	Anticuerpo anti-alfa5beta1; molecula de acido nucleico que codifica el anticuerpo;celula huesped; metodo para produccionde anticuerpos anti-alfa5beta1; inmunoconjugado que comprende el anticuerpo; composicion farmaceutica.
CL2013001831A1 (es)	2013-11-08	Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
CL2014003140A1 (es)	2015-02-27	Anticuerpos aislado que se une a ly6e; metodo de produccion; inmunoconjugado que lo contiene; formulacion farmaceutica que lo contiene y métodos de uso.
JO3519B1 (ar)	2020-07-05	تركيبات أجسام مضادة لأجل cdh19 و cd3
CL2013003640A1 (es)	2014-07-25	Proteina de union a il-17, construccion que comprende dicha proteina, un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de dicha proteina; acido nucleico que la codifica; vector; celula huesped, metodo de produccion; composicion que la comprende; y su uso para reducir la actividad de la il-17 en una patologia en la cual il-17 es perjudicial (div.sol.2129-11).